Better Buy: Compass Pathways vs. Jazz Pharmaceuticals
While both Compass Pathways (NASDAQ: CMPS) and Jazz Pharmaceuticals (NASDAQ: JAZZ) are biopharma companies, their positioning couldn't be more different. Whereas Jazz has a market cap of $8.33 billion, $2.86 billion in trailing revenue, and a pipeline that's chock-full of drug programs of all sorts, Compass is worth $1.48 billion, and it only has a few projects in the works, none of which are near completion.
For investors with little expertise in pharma, it can be tough to weigh the merits of innovative companies like this pair. So let's consider one argument in favor of each stock to see whether Compass Pathways or Jazz Pharmaceuticals might be an appealing addition to your holdings.
Image source: Getty Images.
Source Fool.com
